PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ: PETVW) is an emerging biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals.
PetVivo is one of the many featured companies slated to present at The Microcap Conference 2024, set for Jan. 31-Feb. 1 at Caesars Atlantic City Hotel and Casino. This three-day conference presented by DealFlow Events features technical programming designed for microcap investors and a presenting company track for pitching and socializing.
A brief history of PetVivo
The company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time-efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently FDA-regulated pharmaceuticals and biologics.
The company has a robust pipeline of products for the treatment of animals and people. A portfolio of 20 patents protects the company’s biomaterials, products, production processes and methods of use.
The company’s lead product, Spryng™ with OsteoCushion™ Technology, is a unique product that provides relief from the pain of osteoarthritis in pets and horses. It is a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions, including osteoarthritis, and is currently available for commercial sale to veterinarians.
PetVivo was formed in 1998 and soon developed a protein particle matrix as a medical device.
The National Institute of Health funded the company with an $8 million grant and the Mayo Clinic in Rochester, Minnesota, conducted research and completed the peer review.
“We seldom get challenged on our science because of that,” said CEO, President and Director John Lai, who joined the company in 2013 and became senior executive officer the following year.
“When you’re dealing with veterinary doctors, they want to see the science, even though the product does not require approval for animal use,” he said. “We also provide safety studies.”
Prior to PetVivo, Lai from March 2012 to April 2016 was CEO and a director of Blue Earth Resources, Inc., a small public company which acquired and managed working interests in producing oil and gas leases in Louisiana. Lai has over 30 years of senior executive and operational management and financial experience while holding key executive positions with several public companies in various industries.
In 1992 he founded and until December 2012 was the principal owner and president of Genesis Capital Group, Inc., which provided significant consulting services to many public and private companies in the powersports, technology and other industries, while advising its clients in corporate development, mergers and acquisitions, and private and public capital-raising through equity offerings.
Senior Research Director Dr. Tom Yarbrough recently joined the company. His previous roles include Hospital Director / Chief Surgeon at the Dubai Equine Hospital, where he took care of the UAE royal family’s horses.
Senior Technical Services Veterinarian Dr. Maureen Dower comes to PetVivo by way of the FDA.
“Every one of our people has 20 years or more experience in the field,” said Lai. “We have a seasoned, experienced management team.”
PetVivo’s lead product is widely considered to be an innovation in the treatment of arthritis in animals. And it’s covered by pet insurance, Lai added.
“In the next two weeks we will have the results of multiple safety studies for small animals and efficacy studies,” Lai said. “We will present these findings at the American College of Veterinary Surgeons in Louisville.”
Looking to the future
There is a huge, addressable market for PetVivo’s veterinary treatments. In the United States alone, there are nine million horses, 60 million cats and 83 million dogs.
“What we offer is a very good option, particularly for older animals,” said Lai.
The cost also makes Spryng™ a highly competitive form of alternative treatment to surgery.
A Spryng™ injection is $600-$900 per joint, as opposed to $7,000 or more for surgical procedures with uncertain outcomes and often lengthy rehabilitation for a pet.
Studies show Spryng™ treatments last at least a year with minimal side effects, Lai said.
For a beloved, aging family pet, avoiding surgery may be the best benefit of all.
To learn more, visit PetVivo online.
Tickets to the inaugural Microcap Conference 2024 are going fast. Reserve your seat now for three days of unsurpassed networking and technical discussions of the microcap sector with some of the best names in the business – institutional investors, finance-focused law firms, venture and private equity fund managers, deal advisors, PIPE funds, brokerage firms, investor relations professionals, accredited retail investors and many more. The conference schedule is also packed with entertainment and exciting activities against the backdrop of Atlantic City lights.
Sponsored content, this is a paid promotion
Comments and opinions presented in DealFlow Events publications such as The Microcap Newsletter are solely those of the analysts, corporate executives, and others quoted. They do not represent the opinions of DealFlow Events and DealFlow Events makes no recommendations on whether to buy, sell or hold shares of any particular stock. Investors are advised to conduct their own research before making an investment decision. Neither DealFlow Events nor any of its affiliates hold any position in the stocks mentioned in The Microcap Newsletter.